2023-08-30 09:49:13 ET
More on InflaRx
- InflaRx N.V.: Late Entrant Into The Covid Space
- InflaRx starts public offering of ordinary stock
- InflaRx stock surges as Staidson amends contract on COVID drug, $2.5M equity funding
- InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients
- InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients
- Seeking Alpha’s Quant Rating on InflaRx
- Earnings data for InflaRx
For further details see:
EU regulators accept InflaRX vilobelimab application for review